Skip to content

NR for Parkinson's: NADPARK and the 2026 NOPARK Results

Early studies showed NR raises NAD+. The larger 2026 NOPARK trial found no Parkinson's benefit and worse clinical scores than placebo.

By Marcus HaleLongevity Research Editor
Updated

4 min read · 9 sources

On this page

The case for nicotinamide riboside (NR) in Parkinson's has changed. Early studies showed that it could raise NAD+ in patients. The larger NOPARK trial now argues against using it to modify the disease 9. Understanding why requires separating the original biological findings from the later clinical test.

A result in Parkinson’s disease cannot establish an effect in another neurological condition. The multiple sclerosis research guide explains the separate NR trial and its current evidence limits.

Affiliate partner

MadeMed

NAD+ injection & nasal spray, in 23 states

See MadeMed

Why researchers think NAD+ might matter in Parkinson's

The rationale isn't arbitrary. Parkinson's involves mitochondrial dysfunction and impaired cellular energy metabolism in vulnerable neurons, and NAD+ is central to how cells make energy and run mitochondrial and repair pathways. The hypothesis is that "topping up" NAD+ — using a precursor like nicotinamide riboside (NR) that the body can convert into NAD+ — might support those failing energy systems.

That idea has solid preclinical backing. In laboratory models, the NAD+ precursor NR rescued mitochondrial defects and reduced neuronal loss in induced-pluripotent-stem-cell (iPSC) and fruit-fly models of Parkinson's 1. Reviews of the field now frame NAD+ augmentation as a plausible disease-modifying strategy for neurodegeneration worth testing — while being explicit that it remains unproven in patients 2. So the starting point is a real mechanism and encouraging animal/cell data, not hype. The crucial question is whether any of it translates to people.

The Parkinson's rationale

Mitochondrial dysfunction

Failing neuronal energy in PD

Raise NAD+ with NR

Precursor the body converts to NAD+

Hoped-for: support energy systems

Unproven clinically in patients

The biological rationale explains the research question; it does not establish a treatment benefit.

NADPARK: the landmark Phase I trial

The study that put NAD+ and Parkinson's on the map is NADPARK, a double-blind Phase I trial in Norway 3. Thirty newly diagnosed, treatment-naive PD patients received either 1,000 mg/day of oral NR or placebo for 30 days. Three findings stand out:

  1. It was safe and well tolerated over the month.
  2. It reached the brain. Using phosphorus MRI spectroscopy, the researchers measured a significant — but variable — increase in cerebral NAD levels, confirming oral NR can actually raise brain NAD+ in some people 3.
  3. Responders showed signals worth chasing. Patients whose brain NAD+ rose showed altered cerebral metabolism on PET imaging, and this was associated with mild clinical improvement; NR also nudged down inflammatory markers in blood and cerebrospinal fluid 3.

The authors' own conclusion is the right tone for this whole topic: their findings "nominate NR as a potential neuroprotective therapy" that warrants "further investigation in larger trials" 3. In plain terms: promising enough to keep studying, nowhere near proven.

Strength of evidence

  • Short-term tolerability and target engagementModerate evidence

    NADPARK and NR-SAFE were small monitored studies.

  • Proven disease-modifying benefitNone evidence

    NOPARK did not support this claim.

  • Preclinical rationaleModerate evidence

    Cell and fly findings explain the hypothesis, not patient benefit.

Early biological findings and later clinical outcomes answer different questions.

NR-SAFE: how high can the dose go?

The obvious follow-up question — if some patients didn't raise brain NAD+ much, would a bigger dose help? — drove the NR-SAFE trial 4. This Phase I study gave 20 PD patients 1,500 mg of NR twice daily (3,000 mg/day — triple the NADPARK dose) or placebo for four weeks, with safety as the primary goal.

The high dose was well tolerated, with no moderate or severe adverse events, and it dramatically boosted the blood NAD+ metabolome — up to a roughly 5-fold rise in blood NAD+ 4. There was an improvement in total Parkinson's severity scores (MDS-UPDRS), but the authors were careful to flag a confounder: that change was also linked to how recently patients had taken their levodopa, so it cannot be cleanly credited to NR 4. Serum homocysteine rose mildly early in treatment and then stabilized; whole-blood methyl-donor measurements did not show depletion 4. This was a monitored study, not evidence that high doses are suitable for self-treatment.

So NR-SAFE answered its actual question — high-dose NR is safe short-term and massively raises blood NAD+ — without answering the one patients care about most: does it change the course of the disease?

NOPARK: the larger clinical test

Published in October 2026, NOPARK randomized 410 people with early Parkinson's at 11 Norwegian centers to 500 mg NR twice daily or placebo for 52 weeks; 393 entered the primary analysis. The adjusted MDS-UPDRS difference was 2.72 points, favoring placebo. Four key secondary outcomes were neutral, while nonmotor symptom burden worsened more with NR 9.

This does not support NR as a disease-modifying treatment. Worse clinical scores do not, by themselves, establish accelerated loss of neurons. The result also cannot be transferred automatically to NMN, injections or every neurological condition.

Why raising NAD+ was not enough

NADPARK measured biological delivery; NOPARK tested clinical outcomes. A precursor can succeed at the first and fail at the second. Related human work has likewise found NAD+ changes without matching improvements in physical performance 56. A separate Parkinson's analysis did not establish disruption of methylation homeostasis 7; that is a distinct question from whether treatment helps symptoms.

Cell and fly results 1 and aging experiments in mice 8 explain why researchers tested the idea. They cannot outweigh the more directly relevant clinical trial. Reviews proposing NAD+ augmentation as a strategy 2 should be read alongside the newer results.

What this means for patients and families

NR should not replace established Parkinson's care. People taking it should discuss their reason for use and the new findings with their neurologist; the trial is evidence against a claimed disease-modifying benefit, rather than a reason to alter prescribed Parkinson's medication.

Study findings concern specific formulations, doses, patients and follow-up periods. A commercial NAD+ service or another precursor cannot claim that the early NR brain findings establish its own efficacy. Nor is choosing a higher dose a demonstrated way around a negative clinical result.

What the evidence supports

The early trials provided a reason to investigate NR. The subsequent clinical test did not establish the hoped-for benefit. The larger clinical test should guide interpretation of the earlier biological findings. For the bigger picture of where NAD+ supplementation is genuinely supported and where it isn't, see our pillar guide to the NAD+ evidence, our look at whether NAD+ is really anti-aging, the careful evidence review behind NAD+ and cancer, and the condition-specific findings in NAD+ and NMN for neuropathy.

Frequently asked questions

Can NAD+ or nicotinamide riboside treat Parkinson's disease?

NR is not an established Parkinson's treatment. In the 2026 NOPARK trial, 52 weeks of NR did not improve clinical outcomes and clinical scores favored placebo. The earlier NADPARK and NR-SAFE findings do not override that result.

What did the NADPARK trial actually find?

NADPARK gave 30 newly diagnosed, treatment-naive Parkinson's patients 1,000 mg/day of NR or placebo for 30 days. NR was tolerated over the study period and raised brain NAD+ (variably) on MRI spectroscopy, and in patients whose brain NAD+ rose, was associated with altered brain metabolism and mild clinical improvement plus lower inflammatory markers. The authors framed it as 'nominating' NR for further study — promising, not proven.

Is high-dose nicotinamide riboside safe in Parkinson's?

NR-SAFE found 3,000 mg/day was tolerated over four weeks in 20 participants. Serum homocysteine increased mildly and then stabilized, without measured whole-blood methyl-donor depletion. This small monitored study does not establish long-term safety or clinical efficacy.

Should someone with Parkinson's take an NAD+ supplement?

Discuss supplement use with the treating neurologist. NR has not demonstrated a disease-modifying benefit in Parkinson's and should not replace established care. A supplement's ability to raise NAD+ is not proof that it improves the disease.

References

  1. Schöndorf DC, Ivanyuk D, Baden P, et al. (2018). The NAD+ Precursor Nicotinamide Riboside Rescues Mitochondrial Defects and Neuronal Loss in iPSC and Fly Models of Parkinson's Disease. Cell Reports. https://pubmed.ncbi.nlm.nih.gov/29874584/
  2. Dölle C, Tzoulis C (2025). NAD augmentation as a disease-modifying strategy for neurodegeneration. Trends in Endocrinology & Metabolism. https://pubmed.ncbi.nlm.nih.gov/40287324/
  3. Brakedal B, Dölle C, Riemer F, et al. (2022). The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson's disease. Cell Metabolism. https://pubmed.ncbi.nlm.nih.gov/35235774/
  4. Berven H, Kverneng S, Sheard E, et al. (2023). NR-SAFE: a randomized, double-blind safety trial of high dose nicotinamide riboside in Parkinson's disease. Nature Communications. https://pubmed.ncbi.nlm.nih.gov/38016950/
  5. Elhassan YS, Kluckova K, Fletcher RS, et al. (2019). Nicotinamide Riboside Augments the Aged Human Skeletal Muscle NAD+ Metabolome and Induces Transcriptomic and Anti-inflammatory Signatures. Cell Reports. https://pubmed.ncbi.nlm.nih.gov/31412242/
  6. Martens CR, Denman BA, Mazzo MR, et al. (2018). Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nature Communications. https://pubmed.ncbi.nlm.nih.gov/29599478/
  7. Gaare JJ, Dölle C, Brakedal B, et al. (2023). Nicotinamide riboside supplementation is not associated with altered methylation homeostasis in Parkinson's disease. iScience. https://pubmed.ncbi.nlm.nih.gov/36936793/
  8. Mills KF, Yoshida S, Stein LR, et al. (2016). Long-Term Administration of Nicotinamide Mononucleotide Mitigates Age-Associated Physiological Decline in Mice. Cell Metabolism. https://pubmed.ncbi.nlm.nih.gov/28068222/
  9. Brakedal B, Skeie GO, Derad C, et al. (2026). Nicotinamide Riboside for Patients With Early-Stage Parkinson Disease: The NOPARK Randomized Clinical Trial. JAMA. https://pubmed.ncbi.nlm.nih.gov/42848371/

Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.